secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2026-07-01T12:30:14+00:00
Accession:  0001493152-26-031441
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics settles $2.8M in disputed payables; lien removed, EirGenix obligation cleared
--------------------------------------------------------------------------------

- Settlement extinguishes $2.8 million in disputed accounts payable, reported in Q2 ending June 30, 2026.
- B&I Contractors dismissed crossclaims with prejudice and filed satisfaction of $1.1M mechanics' lien on company property.
- Company paid $1.24M to EirGenix under settlement reducing original $1.7M obligation; final payment on May 26, 2026.
- Two $620k payments (March 3 and May 26, 2026) fully settled disputed EirGenix manufacturing costs.
- All outstanding amounts related to these disputes are fully resolved with no remaining liabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226031441/0001493152-26-031441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226031441/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-031441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer